Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>2007</strong> ANNUAL REPORT 4<br />
H I G H L I G H T S 2 0 0 7<br />
<strong>Pevion</strong>_<strong>Biotech</strong>_<strong>annual</strong>_<strong>report</strong>_<strong>2007</strong>.doc<br />
2 0 0 7 A N N U A L R E P O R T<br />
<strong>Pevion</strong> <strong>Biotech</strong> Acquires License for RSV Vaccine from Ruhr<br />
University Bochum<br />
<strong>Pevion</strong> <strong>Biotech</strong> has acquired a license (partial use rights!) for the RSV vaccine.<br />
The vaccine is based on an optimized expression system for mammalian<br />
cells. In combination with its innovative virosome technology <strong>Pevion</strong> <strong>Biotech</strong><br />
is developing a new vaccine against RSV.<br />
<strong>Pevion</strong> <strong>Biotech</strong> and Mymetics Enter License Agreement<br />
Mymetics has signed an exclusive license for the use of <strong>Pevion</strong> <strong>Biotech</strong>'s<br />
virosome-based technology platform for the development and production of<br />
an HIV vaccine.<br />
EU Grant for <strong>Pevion</strong> <strong>Biotech</strong>'s Malaria Vaccine<br />
The EU has awarded several million euros in grants to a total of 13 European<br />
companies and research institutes, of which <strong>Pevion</strong> <strong>Biotech</strong> received 330,000<br />
euros. The grant was awarded to universities and companies in the field of<br />
malaria research and will support the development and clinical studies of<br />
<strong>Pevion</strong> <strong>Biotech</strong>'s safe and effective multicomponent PeviPRO TM malaria<br />
vaccine.<br />
Due Diligence <strong>2007</strong><br />
In Q1/Q2 <strong>2007</strong> <strong>Pevion</strong> <strong>Biotech</strong> concentrated on the preparation of all<br />
documents which are essential for due diligence.<br />
<strong>Pevion</strong> <strong>Biotech</strong> Secures CHF 35 Million in Series A Financing<br />
Round<br />
In August <strong>2007</strong> <strong>Pevion</strong> <strong>Biotech</strong> closed a CHF 35 million Series A private<br />
financing round. The round was led by the new investor BZ Bank<br />
Aktiengesellschaft. New investors joining the Series A round also include BB<br />
<strong>Biotech</strong> Ventures II, L.P. and CC Private Equity Partners Ltd. The current<br />
investor Bachem Holding <strong>AG</strong> also participated in this financing round.<br />
<strong>Pevion</strong> <strong>Biotech</strong>'s Board of Directors Elects New Members<br />
In September <strong>2007</strong> <strong>Pevion</strong> <strong>Biotech</strong> announced the appointment of Dr. Klaus<br />
Breiner, BB <strong>Biotech</strong> Ventures, and Dr. Joseph Manko, BZ Bank<br />
Aktiengesellschaft, as new members to the company’s board of directors.<br />
<strong>Pevion</strong> <strong>Biotech</strong> Winner of the Life Sciences Prize <strong>2007</strong><br />
The prize, worth 10,000 Swiss francs, was awarded for the fourth time. It<br />
stands under the patronage of the Swiss <strong>Biotech</strong> Association and BioValley<br />
Basel, and is intended for young Swiss companies in the <strong>Biotech</strong>, Pharma<br />
and Medtech sectors. Sponsors of the Swiss Life Sciences Prize are<br />
BioMedinvest, Novartis Venture Fund, Varuma and Venture Incubator.<br />
Strong IP Portfolio<br />
<strong>Pevion</strong> <strong>Biotech</strong> extended its portfolio in <strong>2007</strong> by filing two additional priority<br />
claiming patent applications and one international patent application.
Change language